Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr663 Inhibitors

Olfr663, a member of the olfactory receptor gene family, serves as a key component in the intricate network orchestrating olfactory perception. As a G-protein-coupled receptor (GPCR) arising from single coding-exon genes, Olfr663 shares a 7-transmembrane domain structure with neurotransmitter and hormone receptors. Its role lies in the initiation of a neuronal response triggered by the interaction with odorant molecules, ultimately leading to the perception of smell.

The inhibition of Olfr663 involves a strategic approach targeting both direct and indirect pathways associated with its function. Direct inhibitors, such as muscarinic acetylcholine receptor antagonists like Pirenzepine, act by specifically blocking muscarinic receptors involved in G protein-mediated transduction of odorant signals. On the other hand, indirect inhibitors, exemplified by MEK inhibitors like PD 98059, modulate cellular processes like the MAPK pathway, altering downstream signaling and negatively impacting olfactory receptor gene expression and function. This dual strategy highlights the complexity of the regulatory mechanisms governing Olfr663, providing insights into potential avenues for understanding olfactory perception at the molecular level. The interplay between these inhibitors and Olfr663 illuminates the intricate nature of olfactory signaling and presents opportunities for further exploration in unraveling the nuances of this sensory process.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lidocaine

137-58-6sc-204056
sc-204056A
50 mg
1 g
$51.00
$131.00
(0)

Lidocaine, a sodium channel blocker, indirectly inhibits Olfr663 by modulating neuronal excitability in olfactory receptor cells. Its action reduces the neuronal response to odorant signals.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD 98059, a MEK inhibitor, indirectly inhibits Olfr663 by disrupting the MAPK pathway. This interference alters downstream signaling, negatively impacting olfactory receptor gene expression and function.

(±)-Bay K 8644

71145-03-4sc-203324
sc-203324A
sc-203324B
1 mg
5 mg
50 mg
$84.00
$196.00
$817.00
(0)

Bay K 8644, a calcium channel activator, indirectly influences Olfr663 by enhancing intracellular calcium levels. Elevated calcium negatively modulates GPCR-mediated transduction, inhibiting olfactory perception.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$136.00
$446.00
114
(2)

Thapsigargin, a SERCA inhibitor, indirectly inhibits Olfr663 by disrupting calcium homeostasis. Altered calcium levels negatively impact GPCR-mediated transduction, leading to inhibition of olfactory perception.

Suramin sodium

129-46-4sc-507209
sc-507209F
sc-507209A
sc-507209B
sc-507209C
sc-507209D
sc-507209E
50 mg
100 mg
250 mg
1 g
10 g
25 g
50 g
$152.00
$214.00
$728.00
$2601.00
$10965.00
$21838.00
$41096.00
5
(1)

Suramin, a purinergic receptor antagonist, directly inhibits Olfr663 by blocking purinergic receptors involved in G protein-mediated transduction of odorant signals.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002, a PI3K inhibitor, indirectly influences Olfr663 by disrupting the PI3K pathway. This interference negatively modulates GPCR-mediated transduction, leading to inhibition of olfactory perception.

Calmidazolium chloride

57265-65-3sc-201494
sc-201494A
10 mg
50 mg
$156.00
$612.00
27
(1)

Calmidazolium, a calmodulin inhibitor, indirectly inhibits Olfr663 by disrupting calcium-calmodulin signaling. This interference negatively modulates GPCR-mediated transduction, inhibiting olfactory perception.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin, a PI3K inhibitor, indirectly influences Olfr663 by disrupting the PI3K pathway. This interference negatively modulates GPCR-mediated transduction, leading to inhibition of olfactory perception.